The FDA has approved updated labeling for Asmanex HFA and Dulera to include use in pediatric patients with asthma.
Several studies using both sensor- and chemical-based platforms have confirmed that exhaled volatile organic compounds are sensitive to underlying inflammation.
Endobronchial brush samples from individuals with T2-low inflammation had significantly more fungal diversity compared with those with T2-high inflammation.
Sensitization to Staphylococcus aureus enterotoxins was linked to an increased subsequent risk for severe asthma and asthma exacerbations.
Findings were based on international survey of patients using long-term maintenance medication.